The global biologicals market has witnessed rapid growth in the last few years. According to a recent report from IMARC Group titled “Global Healthcare Cold Chain Logistics Market Report & Forecast: 2012 – 2017”, the global biologicals market grew at a CAGR of 11% in the last five years registering sales worth US$ 109 Billion. This was significantly faster than the 5-6% growth rates experienced by the global pharmaceutical market in the same period.
The report expects that factors such as high efficacy, target oriented attack, higher approval success rates and a very high probability to achieve blockbuster status will continue driving this market in the foreseeable future. According to the firm’s estimates, eight out of the top ten selling drugs in 2016 will be biologicals. This is significantly higher than 2000, where only one product (Epogen/Procrit) managed to make the list of global top ten selling drugs.
The growth potentials presented by biologicals are, however, also accompanied by their own challenges, with one major challenge being transporting them to the patients who need them in an increasingly global market place. The report finds that biologicals are highly temperature sensitive and are recommended to be stored and transported at temperatures ranging from 2°- 8°C. Any failures in the cold chain transportation of the drug can lead to a significant loss of its efficacy and can even make it harmful for the patient. Regulatory agencies in fact say that drugs that have been temperature abused are every bit as dangerous as those that are not authentic.
The report, an updated and far more analytical version of our popular 2011 study, finds that the growth of the biologicals market is creating a huge demand for efficient cold chain logistic services. The study, that has been undertaken using both desk based and qualitative primary market research, has analyzed three aspects of the global healthcare cold chain logistics market.
The first aspect involves the quantification of the global market for temperature sensitive healthcare products into three major classes and evaluation of the current and future opportunities in each of these classes. The second aspect involves an in-depth understanding on the global healthcare cold chain distribution process and logistic requirements for various temperature sensitive healthcare products. The third aspect involves the quantification of the global healthcare cold chain logistic services market and a comprehensive evaluation of its various segments.
To buy the complete report or to get a free sample, please contact:
IMARC Group Asia
Email: apac@imarcgroup.com
Phone: +91-120-415-5099
IMARC Group North America
Email: america@imarcgroup.com
Phone: +1-631-791-1145
IMARC Group Europe, Middle East & Africa
Email:ema@imarcgroup.com
Phone: +44-702-409-7331
For more information, visit: http://www.imarcgroup.com/global-healthcare-cold-chain-logistics-market-report-forecast-2012-2017/
The report expects that factors such as high efficacy, target oriented attack, higher approval success rates and a very high probability to achieve blockbuster status will continue driving this market in the foreseeable future. According to the firm’s estimates, eight out of the top ten selling drugs in 2016 will be biologicals. This is significantly higher than 2000, where only one product (Epogen/Procrit) managed to make the list of global top ten selling drugs.
The growth potentials presented by biologicals are, however, also accompanied by their own challenges, with one major challenge being transporting them to the patients who need them in an increasingly global market place. The report finds that biologicals are highly temperature sensitive and are recommended to be stored and transported at temperatures ranging from 2°- 8°C. Any failures in the cold chain transportation of the drug can lead to a significant loss of its efficacy and can even make it harmful for the patient. Regulatory agencies in fact say that drugs that have been temperature abused are every bit as dangerous as those that are not authentic.
The report, an updated and far more analytical version of our popular 2011 study, finds that the growth of the biologicals market is creating a huge demand for efficient cold chain logistic services. The study, that has been undertaken using both desk based and qualitative primary market research, has analyzed three aspects of the global healthcare cold chain logistics market.
The first aspect involves the quantification of the global market for temperature sensitive healthcare products into three major classes and evaluation of the current and future opportunities in each of these classes. The second aspect involves an in-depth understanding on the global healthcare cold chain distribution process and logistic requirements for various temperature sensitive healthcare products. The third aspect involves the quantification of the global healthcare cold chain logistic services market and a comprehensive evaluation of its various segments.
To buy the complete report or to get a free sample, please contact:
IMARC Group Asia
Email: apac@imarcgroup.com
Phone: +91-120-415-5099
IMARC Group North America
Email: america@imarcgroup.com
Phone: +1-631-791-1145
IMARC Group Europe, Middle East & Africa
Email:ema@imarcgroup.com
Phone: +44-702-409-7331
For more information, visit: http://www.imarcgroup.com/global-healthcare-cold-chain-logistics-market-report-forecast-2012-2017/
Comments
Post a Comment